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associated with an altered immune response to commensal
microbiota, mostly based on increased seroreactivity to
microbial proteins. Although T cells are believed to contribute
to the development of CD, little is known about the antigens
involved. We investigated the antigen-speciﬁcity of T cells iso-
lated from patients with CD. METHODS: We isolated periph-
eral blood mononuclear cells from 65 patients with CD and 45
healthy individuals (controls). We investigated T-cell reac-
tivity to commensal microbial antigens using proliferation
assays (based on thymidine incorporation and carboxy-
ﬂuorescein succinimidyl ester dilution). Gene expression
patterns were determined using microarray and real-time
polymerase chain reaction analyses. Cytokines, chemokines,
and antibodies were measured by enzyme-linked immuno-
sorbent assay, ﬂow cytometry, or multiplex cytokine assays.
Intestinal crypts were obtained from surgical resection spec-
imens of 7 individuals without inﬂammatory bowel disease.
We examined the effects of commensal-speciﬁc CD4þ T cells
on primary intestinal epithelial cells from these samples.
RESULTS: The bacterial proteins FlaX, A4-ﬂa2, and YidX
increased proliferation of CD4þ T cells isolated from periph-
eral blood of patients with CD compared with controls. In
blood samples from controls, CD4þ T cells speciﬁc for FlaX,
A4-ﬂa2, or YidX had a T-helper (Th)1 phenotype; a larger
proportion of CD4þ T cells speciﬁc for these proteins in
patients with CD had a Th17 phenotype or produced Th1 and
Th17 cytokines. When supernatants collected from
commensal-speciﬁc CD4þ T cells from patients with CD were
applied to healthy intestinal epithelial cells, the epithelial cells
increased the expression of the chemokine (C-X-C motif)
ligand 1 (CXCL1), CXCL8 and the CC chemokine ligand 20
(CCL20). CONCLUSIONS: A larger proportion of commensal-
speciﬁc CD4þ T cells from patients with CD have a Th17
phenotype or produce Th1 and Th17 cytokines, compared
with T cells from controls; this might contribute to intestinal
inﬂammation in patients with CD. These cells might be tar-
geted for treatment of CD. The transcriptional data of
commensal-speciﬁc CD4þ T cells from healthy individuals and
CD patients have been deposited in the Gene Expression
Omnibus at the National Center for Biotechnology Information
(accession no: GSE70469).Keywords: Antigen-Speciﬁc Immune Response; IBD; Immunity;
Effector T Cells.rohn’s disease (CD) is a chronic remitting and re-Clapsing inﬂammatory disease of the intestinal tract
that is thought to result from a loss of tolerance to
commensal microorganisms. This view is supported
strongly by studies conducted in animal models of intestinal
inﬂammation, in which pathogenic CD4þ T-cell responses
are directed against the enteric microbiota.1–4
In CD patients, antibodies to several microbial compo-
nents have been detected in serum, indicating an exacer-
bated acquired immune response toward commensal
microbiota. These antibodies recognize microbial compo-
nents such as Saccharomyces cerevisiae oligomannan (anti–
Saccharomyces cerevisiae antibodies [ASCA]),5 Escherichia
coli’s outer membrane protein C (OmpC),6 or various sub-
types of ﬂagellins such as A4-ﬂa2, FlaX, FliC, or CBir1.7–9 The
search for novel bacterial-reacting immunoglobulins in the
serum of CD has led recently to the identiﬁcation of new
E coli–derived seroreactive proteins such as YidX, FrvX, Era,
and GabT.10 Importantly, seroreactivity to microbial antigens
correlates with complicated disease,3,11,12 encouraging the
exploitation of these antibodies as predictors of disease
course.13–15
Although the presence of antimicrobial antibodies in CD
patients6 strongly suggests that a microbial-speciﬁc
T-helper response is generated as well, little evidence has
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toward bacterial antigens in CD patients.16 It generally is
accepted that T cells, and more speciﬁcally CD4þ T cells,
play a pathogenic role in CD because they heavily inﬁltrate
involved areas of the intestinal mucosa and extensive data
from experimental models support this.17 These cells show
T-helper (Th)1 and Th17 proinﬂammatory proﬁles.18–22
Despite being regarded as pathogenic key players in CD,
their antigen speciﬁcity remains largely unexplored. Most of
the studies that have focused on T-cell reactivity to the in-
testinal microbiota used total bacterial sonicates or bacterial
protein pools to stimulate T cells. Although these data
showed that T cells from CD patients overreacted to intes-
tinal bacteria, no speciﬁc antigens were identiﬁed.23–25
More recently, the group of Targan,16 based on ﬁndings in
animal models of inﬂammatory bowel disease, were able to
detect CBir1-reactive T cells in CD patients.
Deﬁning an antigen-speciﬁc, T-cell response in the
context of CD would have many implications. From a path-
ophysiological point of view, it would reinforce the concept of
loss-of-tolerance toward commensal organisms. Moreover, it
will enable exploring the nature and function of such cells.
From a clinical point of view, it also may provide a possible
mechanism for disease relapse and damage progression, as
well as potential new speciﬁc therapeutic targets.
We therefore set out to investigate the T-cell response to
several commensal bacterial- and yeast-derived proteins in
CD patients. Our data provide evidence of the existence of
commensal microbial-speciﬁc CD4þ T cells in healthy in-
dividuals and in CD patients. More importantly, we show
that although commensal-speciﬁc CD4þ T cells from healthy
controls show a Th1 phenotype, these cells present a unique
Th17-biased transcriptional and functional proﬁle in CD
patients and they are able to amplify the inﬂammatory
response in the intestinal epithelium. Based on these ﬁnd-
ings, we hypothesize that speciﬁcally targeting these
microbial-reacting T cells could represent a novel and
effective approach to CD treatment.Materials and Methods
More detailed information is provided in the online
Supplementary Materials and Methods section.
Study Subjects
Patients diagnosed with CD (N ¼ 65) by endoscopic, histo-
logic, and radiologic criteria were recruited for the study. Healthy
volunteers (N ¼ 45) without any known underlying acute or
chronic pathologic condition served as control donors. Epithelial
crypts were obtained from surgical resection specimens from
non–inﬂammatory bowel disease (IBD) individuals (N ¼ 7)
undergoing surgery for colorectal cancer; the healthymucosawas
separated from the lesion by at least 10 cm. Demographic and
clinical characteristics are summarized in Supplementary Table 1.
This study was approved by the Ethics Committee at the Hospital
Clínic de Barcelona and was performed in accordance with the
principles stated in the Declaration of Helsinki. All patients,
healthy controls, and non-IBD subjects signed an informed con-
sent before their inclusion in the study.Antigen Stimulation of Peripheral Blood
Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized peripheral blood by Ficoll (Sigma-Aldrich,
Madrid, Spain) gradient centrifugation. For T-cell proliferation
screening, PBMCs were cultured with the microbial commensal
antigens ASCA-Ag (Saccharomyces Cerevisiae oligomannan;
antigen recognized by ASCA), CBir1, FlaX, A4-ﬂa2, and YidX
(Prometheus Laboratories, Inc, San Diego, CA) at 1 mg/mL for 7
days. 3H thymidine (1 mCi/well; Amersham, Cambridge, United
Kingdom) incorporation took place during the last 16 hours of
culture. For major histocompatibility complex II blocking,
anti–HLA-DR, -DP, and -DQ (BD Biosciences, Franklin Lakes, NJ)
was added at 20 mg/mL to the culture. For carboxyﬂuorescein
succinimidyl ester (CFSE) (Cell Trace CFSE cell proliferation kit;
Thermo Fisher Scientiﬁc, Waltham, MA) staining, PBMCs were
incubated with CFSE at 5 mmol/L and cultured with tetanus
toxoid (TT; Sigma-Aldrich) and microbial commensal antigens
(Prometheus Laboratories, Inc) all at 2 mg/mL for 7 days.
Cytokine Analysis
For intracellular cytokine staining, cells were restimulated
with phorbol myristate acetate and ionomycin in the presence of
brefeldin A (all from Sigma-Aldrich) for the ﬁnal 4 hours of
culture. Cells were ﬁxed and permeabilized with FIX and PERM
(Thermo Fisher Scientiﬁc). Cells were stained with a Live/Dead
ﬁxable violet dead cell stain kit (Thermo Fisher Scientiﬁc) and
ﬂuorescent antibodies. Cells were acquired in a Fluorescence-
Activated Cell Sorting Canto II (BD Biosciences) and analyzed
with BD Fluorescence-Activated Cell Sorting Diva Software
v6.1.1.
Cytokine secretion by PBMCs was measured by an enzyme-
linked immunosorbent assay or using the multiplex cytokine
assay Milliplex Human Th17 magnetic bead (EMD Millipore
Corporation, Billerica, MA).
Cell Sorting of Antigen-Speciﬁc CD4þ T Cells
and RNA Isolation
CFSE-labeled PBMCs were cultured in the presence of TT,
FlaX, A4-ﬂa2, or YidX antigens. Recombinant interleukin (IL)2
(20 IU/mL) was added to the culture on day 7. Viable CFSE-
CD4þ cells were sorted on day 14 of culture in a Fluorescence-
Activated Cell Sorting Aria II (BD Biosciences) and restimulated
with antigen in the presence of autologous irradiated PBMCs.
Ten days later RNA was extracted.
Intestinal Crypt Isolation and Culture
Non-IBD intestinal epithelial crypts were isolated from in-
testinal tissue as previously described.26 For short-term crypt
culture, 30 isolated crypts/25 mL Matrigel (BD Biosciences) were
plated and cultured in either complete crypt culture medium or
in medium containing supernatants from activated sorted
antigen-speciﬁc CD4þ T cells. Antigen-speciﬁc T-cell superna-
tants were obtained from restimulating sorted cells with anti-
CD3 (BD Biosciences) and anti-CD28 (BD Biosciences) at
1 mg/mL for 5 days. Neutralization of IL17 was achieved by
preincubation of T-cell supernatants with monoclonal anti-IL17A
(R&D Systems, Minneapolis, MN). After overnight culture of
crypts, RNA was extracted. Chemokine analysis in culture
Figure 1. Enhanced proliferative response to commensal microbial antigens in CD patients. (A) Proliferation was measured by
3H-thymidine incorporation in PBMCs from healthy controls (n ¼ 11) and CD patients (n ¼ 16) cultured in the presence of
microbial antigens for 7 days. Stimulation index (SI): counts per million from stimulated cells/counts per million unstimulated
controls. A dashed line was set at a stimulation index of 2 and indicates the threshold for antigen-speciﬁc proliferation. (B)
Proliferation measured by 3H-thymidine incorporation of PBMCs from CD patients (n ¼ 3) cultured with microbial antigens in
the presence of a human anti–major histocompatibility complex (MHC)-II antibody (anti–HLA-DP-DR-DQ) or isotype control
(mIgG2a) for 7 days. (C) Representative ﬂuorescence-activated cell sorting dot plots of CFSE dilution of CD4þ T cells after 7
days of culture with YidX. Numbers indicate the frequency of CFSE- cells among live CD4þ T cells. (D) Percentage of CFSE-
CD4þ T cells in CFSE-labeled PBMCs from healthy controls (n ¼ 18) and CD patients (n ¼ 21). Means ± SEM. ns > .05, *P 
.05, **P < .01.
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assay following the manufacturer’s instructions (R&D Systems).
Statistical Analysis
For 2-group comparisons, the 2-tailed Mann–Whitney–
Wilcoxon test was used. One-way analysis of variance was per-
formed using the Kruskal–Wallis statistics test or the Friedman
test, both followed by the Dunn post-test. Data associations were
analyzed using a Spearman rank correlation test. Statistical an-
alyses were performed using Prism4 (Graphpad Software, San
Diego, CA). Error bars show themean and SEM. P values of .05 or
less were considered statistically signiﬁcant.
Results
Enhanced CD4þ T-Cell Proliferation to
Commensal Microbial Antigens in CD Patients
We ﬁrst measured PBMC proliferation to ASCA-Ag, CBir1,
FlaX, A4-ﬂa2, and YidX. These antigens were selected basedon reported increased sera reactivity in CD.7,9,10,27 CD pa-
tients (n ¼ 16) showed a signiﬁcantly higher stimulation in-
dex (deﬁned as the fold-change in proliferation compared
with unstimulated PBMCs) than healthy controls (n ¼ 11) in
response to FlaX, A4-ﬂa2, and YidX stimulation (Figure 1A).
The detected cell proliferation was attributable to antigen-
speciﬁc-CD4þ T cells because it was abrogated speciﬁcally by
an anti–major histocompatibility complex-II–blocking anti-
body (Figure 1B). To identify and further characterize
antigen-responding CD4þ T cells, we used a CFSE-based
dilution assay to quantify the percentage of CD4þ T cells
that proliferated upon antigen stimulation (Figure 1C). TT
was included in this assay as a non–commensal-derived
bacterial antigen. An independent cohort of healthy controls
(n ¼ 18) and CD patients (n ¼ 21) was used for this mea-
surement; of those, 6 CD patients overlapped with data in
Figure 1A. Similar to the total PBMC proliferation measured
by thymidine incorporation, the percentage of proliferating
(CFSE-) CD4þ cells was signiﬁcantly higher in CD patients
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but not ASCA-Ag or CBir1 stimulation (Figure 1D). In contrast,
the proliferative CD4þ T cell response to TT was comparable
in CD patients and controls, strongly suggesting that
increased reactivity to microbial components is a character-
istic feature of CD patients.
We focused on FlaX, A4-ﬂa2, and YidX because they
drive higher PBMC proliferation (Figure 1A and D) in CD
patients and analyzed the co-occurrence of antigen-speciﬁc
T-cell reactivity. According to data shown in Figure 1A,
75% of CD patients (12 of 16) reacted to at least 1 of the
3 bacterial proteins (stimulation index, 3); of those, 83%
(10 of 12) responded to more than one antigen
(Supplementary Figure 1A). Regarding patients included in
Figure 1D, more than 60% (14 of 21) showed CD4þ T cell
reactivity to at least 1 of the 3 bacterial proteins. Of those,
78% (11 of 14) responded to more than 1 bacterial protein
(Supplementary Figure 1B).
Next, we determined serologic responses to FlaX, A4-ﬂa2,
and YidX in CD patients (n ¼ 19) and healthy controls
(n ¼ 17) for whom we had measured the antigen-speciﬁc
CD4þ T-cell response (Figure 1D). Supplementary Figure 2A
shows the comparative scatterplot of IgG serologic responses
to FlaX, A4-ﬂa2, and YidX in CD patients. Serologic positivity
to each antigen was determined as described in the
Supplementary Materials and Methods section.
More than 70% (14 of 19) presented with either a CD4þ
T cell and/or an antibody response. Eighty-ﬁve percent of
those (12 of 14) had combined serologic and CD4þ T-cell
responses to at least 1 of the 3 antigens (Supplementary
Figure 2B). Regarding each independent antigen, we found
that 54% (6 of 11), 58% (7 of 12), and 58% (7 of 12) of the
patients presented combined CD4þ T cell and antibody
responses to FlaX, A4-ﬂa2, and YidX, respectively
(Supplementary Figure 2C).
Overall we show that CD patients have increased pro-
liferative CD4þ T-cell responses to FlaX, A4-ﬂa2, and YidX,
and that these correlate in most individuals with the pres-
ence of speciﬁc IgG in serum.
We also analyzed the association of antigen-speciﬁc
T cell and antibody responses with the patients’ character-
istics (included in Supplementary Table 1), and treatment at
the time of the study. Although we did not ﬁnd any signif-
icant association between the T-cell responses and any of
the patient variables (data not shown), we did observe a
positive association between the presence of YidX-speciﬁc
antibodies and disease location because a higher number
of patients with a positive serologic response present with
ileocolonic (L3) disease (Supplementary Figure 3A). Inter-
estingly, the presence of YidX-speciﬁc antibody responses
also correlated positively with longer disease duration
(Supplementary Figure 3B).FlaX-, A4-ﬂa2-, and YidX-Speciﬁc CD4þ T Cells
From CD Patients Show a Th1 and Th17
Proinﬂammatory Phenotype
To deﬁne the cytokine proﬁle of microbial antigen-
driven T-cell responses, we ﬁrst measured interferon(IFN)-g and IL17 in culture supernatants of total PBMCs
stimulated for 7 days with TT, ASCA-Ag, CBir1, FlaX, A4-ﬂa2,
and YidX. We looked at IFN-g and IL17 because they are
characteristic of Th1 and Th17 responses, respectively, both
of which have been associated with gut inﬂammation in
CD.28 Both cytokines were increased signiﬁcantly in CD
compared with control supernatants in response to FlaX,
A4-ﬂa2, and YidX (Supplementary Figure 4A and B). IFN-g
also was overproduced signiﬁcantly by CD patients in
response to ASCA-Ag, however, there was no difference in
IL17 secretion. No differences in cytokines secretion were
detected in response to CBir1. Interestingly, neither IFN-g
nor IL17 secretion induced by stimulation of PBMCs with
the noncommensal antigen TT were signiﬁcantly different in
CD compared with healthy controls.
To speciﬁcally measure cytokine production by antigen-
speciﬁc CD4þ T cells, we performed intracellular IFN-g and
IL17 staining on CFSE-labeled PBMCs cultured with TT,
FlaX, A4-ﬂa2, or YidX (Figure 2A) in an independent group
of CD patients and controls. We observed that TT-speciﬁc
CD4þ T cells mainly produced IFN-g (Figure 2B), both in
healthy individuals and CD patients. In contrast, FlaX-, A4-
ﬂa2–, and YidX-speciﬁc CD4þ T cells presented a mixed
IFN-g and IL17 proﬁle. Although the percentage of single
IFN-gþ IL17- cells (Th1) was similar for CD patients and
controls (Figure 2B), the frequency of IL17-producing T
cells was signiﬁcantly higher in the former. Remarkably, we
noted signiﬁcantly higher frequencies of IL17þ IFN-g- single-
(Th17) and IL17þ IFN-gþ double-positive (Th17/Th1) CD4þ
T cells that recognized FlaX, A4-ﬂa2, and YidX in CD patients
compared with control individuals (Figure 2C and D). These
data indicate that commensal-speciﬁc CD4þ T cells in CD
patients present a Th17 and Th17/Th1 phenotype upon
antigen recall that was not observed in T cells responding to
the same antigen in healthy controls.Commensal Antigen-Speciﬁc CD4þ T Cells
From CD Patients Present a Th17-Related
Transcriptional Signature
Next, we stimulated CFSE-labeled PBMCs with the
commensal antigens FlaX, A4-ﬂa2 or YidX, and sorted out
CD4þ CFSE- (proliferating) cells from a different cohort of
CD patients and healthy controls. Freshly sorted cells then
were restimulated with their cognate antigen, and autolo-
gous irradiated PBMCs were used as antigen-presenting
cells. Total RNA from expanded antigen-speciﬁc T cells
then was isolated. The whole genomic transcriptional
signature of a pool of FlaX-, A4-ﬂa2–, and YidX-speciﬁc CD4þ
T cells was interrogated by microarray analysis and
compared CD individuals (n ¼ 10) with healthy controls
(n ¼ 8). Differential expression analysis of the microarray
identiﬁed 299 genes whose expression was signiﬁcantly
different in CD patients compared with controls (P  .05;
jFCj  1.5) (Figure 3 and Supplementary Table 2). Among
these genes, 37 belonged to the Th17 and Th17.1 tran-
scriptional signatures (marked in purple in Figure 3), as
described by Ramesh et al.29 This included the up-
regulation of CCR6, IL17F, RORC, CCL20, and IL26 in CD
Figure 2. FlaX-, A4-ﬂa2–, and YidX-speciﬁc CD4þ T cells from CD patients show a Th17/Th1 proinﬂammatory phenotype.
CFSE-labeled PBMCs from healthy controls (n ¼ 8) and CD patients (n ¼ 9) were cultured alone or in the presence of TT, FlaX,
A4-ﬂa2, or YidX antigen for 7 days. (A) Representative ﬂuorescence-activated cell sorting plots for IFN-g and IL17 staining
gated on live CFSE- CD4þ T cells stimulated with YidX. (B) Frequency of IFN-gþ IL17-, (C) IL17þIFN-g-, (D) IL17þIFN-gþ among
live CFSE-CD4þ T cells. Means ± SEM. ns > .05, *P  .05, **P < .01. MHC, major histocompatibility complex; SI, stimulation
index.
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genes such as PTGER2 were down-regulated. To validate the
microarray data, a number of Th1 and Th17 signature genes
were identiﬁed by real-time polymerase chain reaction in an
independent group of samples from healthy controls (n ¼ 5)
and CD patients (n ¼ 6). Real-time polymerase chain reac-
tion analysis showed higher expression of RORC, IL17A, and
IL17F in FlaX-, A4-ﬂa2–, and YidX-speciﬁc T cells from CD
patients compared with healthy controls (Figure 4A–C). Also
in agreement with microarray data, expression of CCR6 and
PTGER2 was signiﬁcantly up- and down-regulated, respec-
tively, in A4-ﬂa2– and YidX-speciﬁc T cells from CD patients,
but not in FlaX-speciﬁc T cells (Figure 4D and E). In addi-
tion, the expression of CCL20 was higher in A4-ﬂa2– and
YidX-speciﬁc T cells from CD patients compared with con-
trols (Figure 4F). Importantly, the Th1 signature genes
TBX21 and IFNG, and tumor necrosis factor (TNF)A, were
expressed similarly in healthy controls and CD microbial
antigen-speciﬁc T cells (Figure 5).
To investigate the clonality of antigen-speciﬁc T cells, we
analyzed the T-cell receptor (TCR) repertoire of TT-, FlaX-,
A4-ﬂa2–, and YidX-speciﬁc CD4þ T cells by measuring the
complementarity determining region 3 distribution length
using spectratyping. We observed a diverse TCR repertoire
for the 3 commensal-speciﬁc T cells in all individuals withfew monoclonal expansions within the TCR b-variable re-
gion. However, we did not detect a bias in TCR b-variable
use, excluding the possibility of a superantigen-driven
expansion (Supplementary Figure 5).Activated Commensal Antigen–Speciﬁc CD4þ
T Cells From CD Patients Promote Epithelial
Inﬂammatory Responses
To further characterize commensal-speciﬁc T cells from
CD patients, we analyzed the expression of the intestinal-
homing integrin b7 on antigen-speciﬁc CD4þ T cells in a
total of 10 patients. We observed signiﬁcantly higher
expression of b7 in FlaX-, A4-ﬂa2–, and YidX-speciﬁc T cells
compared with TT-speciﬁc T cells from CD patients
(Supplementary Figure 6). Given their characteristic Th17-
biased phenotype, as well as their relative increase in b7
surface expression, we asked whether these cells could
drive inﬂammation in the intestinal mucosa. To test the ef-
fect of antigen-speciﬁc T cells from CD patients on healthy
intestinal epithelium, we isolated whole intestinal crypts
from non-IBD surgical specimens (Figure 6A) and cultured
them in the presence of supernatants from activated sorted
TT-, FlaX-, A4-ﬂa2–, and YidX-speciﬁc CD4þ T cells obtained
from an independent cohort of CD patients (n ¼ 5).
Figure 3. FlaX-, A4-ﬂa2–,
and YidX-speciﬁc CD4þ T
cells from CD patients
present Th17-biased tran-
scriptional proﬁles. Differ-
entially expressed genes
by commensal microbial
antigen (FlaX, A4-ﬂa2, and
YidX)-speciﬁc CD4þ T
cells of healthy controls
(n ¼ 8) and Crohn’s dis-
ease patients (n ¼ 10)
based on microarray anal-
ysis (P  .05 and jfold-
changej  2). Each row
shows 1 individual probe
(299 differentially
expressed genes) and
each column shows an
experimental sample.
Genes related to the Th17
and Th17.1 transcriptional
signatures are marked in
purple. An unsupervised
hierarchical cluster
method using Pearson
distance and average link-
age method was applied
for gene and sample
classiﬁcation.
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from anti-CD3/anti-CD28–activated commensal anti-
gen–speciﬁc CD4þ T cells induced higher transcriptional
expression (Figure 6B and 6D) and protein secretion
(Supplementary Figure 7A and B) of the neutrophil-
recruiting chemokines CXCL8 and CXCL1 compared with
crypts that had been cultured with medium alone. Of note,
crypts treated with supernatants from activated TT-speciﬁc
CD4þ T cells did not up-regulate CXCL1 or CXCL8 expres-
sion. Supernatants of commensal-speciﬁc T cells also
induced higher expression of CCL20, a chemoattractant for
CCR6-expressing Th17 cells, on non-IBD intestinal crypts
(Figure 6C) compared with those treated with supernatants
derived from TT-speciﬁc T cells; nonetheless, the differ-
ences compared with nonactivated crypts were not signiﬁ-
cant. In contrast, we observed that supernatants from TT
induced higher transcriptional and protein expression of the
Th1-attracting chemokine CXCL10 compared with unsti-
mulated crypts (Figure 6E and Supplementary Figure 7C).
These results suggest that commensal-speciﬁc T cells fromCD patients prompt a predominant neutrophil and Th17
recruitment to the intestinal epithelium.IL17 Regulates Proinﬂammatory Chemokine
Expression by Intestinal Epithelial Crypts
We next determined which cytokines were present in
the T-cell supernatants used to stimulate intestinal epithe-
lial crypts. As predicted by their transcriptional signatures,
FlaX-, A4-ﬂa2–, and YidX-speciﬁc T-cell supernatants
contained high amounts of IL17A, IL17F, IL22, and
CCL20 (Supplementary Figure 8A–D), whereas TT-speciﬁc
T-cell supernatants contained very low concentrations of
these cytokines. In contrast, we measured similar amounts
of IFN-g (Supplementary Figure 8E) and TNF-a
(Supplementary Figure 8F) in all supernatants regardless of
antigen speciﬁcity.
It has been observed that IL17 and TNF-a can act syn-
ergistically to drive CXCL8, CXCL1, and CCL20 expression on
epithelial cell lines, whereas IL17 represses the expression
Figure 4. Differential expression of Th17-related genes by commensal antigen-speciﬁc CD4þ T cells from CD patients.
Messenger RNA expression of (A) RORC, (B) IL17A, (C) IL17F, (D) CCR6, (E) PTGER2, and (F) CCL20 genes assessed by real-
time polymerase chain reaction in sorted antigen-speciﬁc CFSE- CD4þ T cells from healthy controls (n ¼ 5) and CD patients
(n ¼ 6). Arbitrary units (AU) relative to b-actin expression. Means ± SEM. ns > .05, *P  .05, **P < .01.
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similar effect on primary intestinal epithelial crypts upon
the addition of recombinant IL17 (r-IL17) and TNF-a
because they induced increased CXCL8, CXCL1, and CCL20
transcriptional expression (Supplementary Figure 9A–C). In
contrast, CXCL10 expression was inhibited when r-IL17 was
added to the culture (Supplementary Figure 9D). Interest-
ingly, neutralization of IL17 reduced the synergistic effect of
r-IL17 and recombinant TNF-a in the induction of CXCL8,
CXCL1, and CCL20 (Supplementary Figure 9A–C), but it
restored CXCL10 expression (Supplementary Figure 9D). In
line with this, the effect of FlaX-, A4-ﬂa2–, and YidX-speciﬁc
T-cell supernatants on CXCL8, CXCL1, and CCL20 expressionFigure 5. Th1-related genes and TNFA are not expressed differe
healthy controls. Messenger RNA expression of (A) TBX21, (B) I
chain reaction in sorted antigen-speciﬁc CFSE- CD4þ T cells fro
units (AU) relative to b-actin expression. Means ± SEM. ns > .0in intestinal crypts was reduced upon neutralization of IL17
(Figure 7A–C). It is worth noting that neutralization of IL17
in commensal-speciﬁc T-cell supernatants induced higher
expression of CXCL10 on intestinal crypts (Figure 7D).Discussion
The loss of tolerance toward commensal bacteria as a
mechanism driving CD is widely accepted. To date, it is
mostly understood as increased seroreactivity toward a
variety of microbial antigens in CD.12,13,31–33 This suggests
the existence of helper T cells reacting to the same
commensal microorganisms. Despite the fact that CD4þ Tntly by commensal antigen–speciﬁc CD4þ T cells from CD and
FNG, and (C) TNFA genes assessed by real-time polymerase
m healthy controls (n ¼ 5) and CD patients (n ¼ 6). Arbitrary
5.
Figure 6. Activated FlaX-,
A4-ﬂa2–, and YidX-
speciﬁc CD4þ T cells
from CD patients promote
intestinal inﬂammation. (A)
Representative picture of
whole intestinal crypts
from non-IBD surgical
specimens after 18 hours
of culture. Relative gene
messenger RNA expres-
sion of (B) CXCL8, (C)
CCL20, (D) CXCL1, and (E)
CXCL10 in intestinal
crypts cultured with su-
pernatants from activated
antigen-speciﬁc CD4þ T
cells from CD patients (n ¼
5). Means ± SEM. ns >
.05, *P  .05, **P < .01.
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still are limited data on the antigen speciﬁcity of the T-cell
response in CD.16,23,25,34,35
Here, we provide novel evidence of the existence of
commensal microbial-speciﬁc CD4þ T cells in the peripheral
blood of both CD patients and healthy individuals. Impor-
tantly, proliferation in response to commensal antigen
stimulation was enhanced in CD patients compared with
healthy controls. The fact that healthy individuals present
with circulating commensal-speciﬁc CD4þ T cells is not
completely unexpected. In fact, a T-cell responses to E coli
proteins have been observed previously in healthy sub-
jects.35 In other immune-mediated diseases, such as multi-
ple sclerosis, T-cell reactivity to self-antigens (myelin) has
been reported in healthy controls despite the fact that
myelin-speciﬁc T cells showed increased activation in mul-
tiple sclerosis patients36,37 and a different functional in-
ﬂammatory proﬁle.38 Moreover, it has been described
recently that healthy individuals present IgG antibodies to
gut microbial antigens in serum, suggesting that microbial-
speciﬁc CD4þ T-cell helper cells can similarly develop in
the absence of CD.39A key ﬁnding of our study was that FlaX-, A4-ﬂa2–, and
YidX-driven CD4þ T-cell responses in CD patients showed a
distinct inﬂammatory phenotype, a response characterized
by secretion of high amounts of TNF-a, IFN-g, IL17A, IL17F,
and CCL20. These differences were conﬁrmed by tran-
scriptional analysis of sorted FlaX, A4-ﬂa2, and YidX-speciﬁc
CD4þ T cells. Through this analysis we identiﬁed signiﬁcant
differences in the expression of RORC, IL17A, IL17F, CCR6,
CCL20, and PTGER2 in commensal-speciﬁc T cells from CD
patients compared with control subjects. In contrast, we
observed no difference in Th1-related genes and TNFA be-
tween these 2 groups.
Importantly, the percentage of Th17 and Th17/Th1 cells
among commensal-speciﬁc CD4þ T cells in CD patients was
remarkably higher than in healthy controls. In fact, Th17/
Th1 cells have been found in CD at unusually higher rates,
together with conventional Th1 and Th17 cells.28,40 It also
has been postulated that pathogenic Th17 cells can be found
within the Th17/Th1 (Th17.1) subset in CD,29 suggesting
that FlaX-, A4-ﬂa2–, and YidX-speciﬁc T cells play a proin-
ﬂammatory role in CD. Data in experimental models show
that Th17 cells can give rise in vivo to Th1 cells and that this
Figure 7. IL17 neutraliza-
tion reduces the expres-
sion of neutrophil and
Th17-recruiting chemo-
kines by intestinal epithe-
lial crypts. Chemokine
levels of (A) CXCL8, (B)
CCL20, (C) CXCL1, and (D)
CXCL10, on intestinal
crypts after 18 hours of
culture with supernatants
from activated antigen-
speciﬁc CD4þ T cells
from CD patients pre-
treated with anti-IL17
monoclonal antibody (n ¼
4). Chemokine levels after
stimulation with untreated
supernatants were set as
the 100% value for each
donor (dashed line), and
expression for stimulation
with anti-IL17–treated su-
pernatants is shown as the
percentage thereof. Means
± SEM.
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Remarkably, this study also showed that Th17 also sup-
ports the de novo generation of pathogenic Th1 cells.
To provide additional speciﬁcity to our observations, we
included throughout our study a noncommensal bacterial
protein (TT) for which all appropriately vaccinated in-
dividuals presented memory TT-speciﬁc CD4þ T cells in
peripheral blood. We show that the CD4þ T-cell proliferative
response to the disease-unrelated protein TT is comparable
in CD patients and healthy controls. Moreover, TT elicits a
predominantly Th1 response both in CD and in healthy
controls. Collectively, this would show that CD4þ T cells
from CD patients are not generally biased toward a highly
proliferative Th17 phenotype, but rather that this response
is geared speciﬁcally toward deﬁned gut commensal anti-
gens. The marked differences among commensal-speciﬁc T
cells from healthy controls and CD patients suggest that
despite reacting to the same protein antigens, their priming
may have taken place in strikingly different environments.
This notion is supported further by the fact that TT-speciﬁc
T cells, which have been primed in the presence of the same
vaccine adjuvant (alum) in both healthy controls and CD
patients, do not show functional differences among patients
and controls. In addition, it has been shown that during
gastrointestinal infection with Toxoplasma gondii,
commensal-speciﬁc T cells (CBir1 transgenic T cells)
differentiated into Th1 cells, while giving rise to Th17 cells
upon chemical disruption of the epithelial barrier in mice.
These data thus indicate that microbiota-speciﬁc T cells are
shaped by signals provided by the inﬂammatory milieu
rather than by antigen speciﬁcity.42Interestingly, a recent genetic study in IBD patients
identiﬁed a causal association between the HLA-II allele
HLR-DRB1*01:03 and CD,43 indicating that the adaptive
immune response plays a central role in CD. This study
supports our ﬁndings and the notion that antigen-speciﬁc
CD4þ T cells could contribute to intestinal inﬂammation in
the context of CD.
It is likely that these circulating commensal-speciﬁc T
cells in CD patients are recruited to the intestinal mucosa
during disease ﬂares. In fact, we show that commensal-
speciﬁc T cells present an overall higher b7 expression
proﬁle compared with TT-speciﬁc cells in CD patients. High
b7 (which in peripheral blood is associated primarily with
a4) favors binding to the endothelial adhesion molecule
mucosal vascular addressin cell adhesion molecule 1
(MAdCAM-1), which is expressed constitutively by high
endothelial venules and the inﬂamed intestinal vascular
endothelium. To test the proinﬂammatory potential of
commensal-speciﬁc T cells from CD patients in the intestine,
we cultured non-IBD primary epithelial crypts with
T-cell–derived supernatants. Importantly, we found that the
cytokine cocktail produced by commensal-speciﬁc T cells,
but not by noncommensal-speciﬁc T cells (TT), in CD pa-
tients elicited a proinﬂammatory response in intestinal
epithelial crypts (higher expression of CXCL1, CXCL8, and
CCL20). Thus, this effect may be promoted by the synergy
between IL17A and other secreted cytokines such as TNF-a
(all highly secreted by commensal-speciﬁc CD T cells). This
would be in agreement with our observation regarding
primary intestinal epithelial cells and other studies
involving recombinant IL17 and TNF-a on intestinal
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commensal-speciﬁc T cells, which show a mixed Th17/Th1
phenotype, may exacerbate intestinal inﬂammation by
creating a feedback loop that favors the accumulation of
Th17 cells (CCL20) and neutrophils (CXCL1 and CXCL8) at
the site of inﬂammation.
An important issue we addressed was whether CD4þ
T-cell responses to microbial antigens occurred simulta-
neously with the presence of speciﬁc antibodies in serum.
We observed that, in most patients, CD4þ T-cell responses
to FlaX, A4-ﬂa2, or YidX were accompanied by serologic
responses to the antigens studied. Although the number of
patients may be too low to make any deﬁnitive conclusions,
our results suggest that detection of speciﬁc antibodies to
these antigens can act as a reliable surrogate marker for the
presence of the cognate T-helper response in CD patients.
Remarkably, anti-YidX antibodies in serum independently
correlated with ileocolonic disease location and with long-
term disease despite the small number of patients
analyzed. Previous studies using larger cohorts of CD pa-
tients identiﬁed correlations between antibodies to other
microbial proteins with complicated disease behavior,
including small-bowel disease location.3,8
Although our study does not provide data on the
microbial-speciﬁc response in ulcerative colitis (UC), it has
been described previously that YidX-speciﬁc serologic re-
sponses are more abundant in UC patients, in relation to
other microbial components, compared with CD patients.10
However, antibody responses to FlaX and A4-ﬂa2 arise in
only a small percentage (6%) of UC patients compared with
CD patients (57% and 59%, respectively).8 Because
increasing evidence has indicated that Th17 cells may be
important contributors to intestinal inﬂammation in UC,19 it
would be interesting to investigate the antigen speciﬁcity of
T cells in patients with UC, in particular to YidX.
Overall, our data would point to IL17 as a desirable
target in treating CD. Nonetheless, recent clinical data un-
expectedly showed the negative effects of such therapy in 2
phase II studies,44,45 despite having shown efﬁcacy in other
immune-mediated diseases.46 The results of these clinical
trials highlighted the important role of IL17 in controlling
microbial and fungal growth in subjects with ongoing
mucosal ulceration because its blockade induced severe
infections, including mucocutaneous candidiasis in treated
patients. Furthermore, IL17 also is produced by other im-
mune cells in the intestine, such as innate-like lymphocytes,
natural killer cells, natural killer–T cells, and T-regulatory
cells, which may play an important role in the regulation of
intestinal homeostasis.47,48 The identiﬁcation and charac-
terization of commensal-speciﬁc CD4þ T cells offers the
opportunity to speciﬁcally target potential pathogenic CD4þ
T cells without altering other IL17-producing immune cells
that may be beneﬁcial to control fungal growth and intes-
tinal homeostasis. Targeting FlaX-, A4-ﬂa2–, and YidX-
speciﬁc CD4þ T cells, as opposed to blocking IL17 alone,
may offer a valuable therapeutic option because it may
impact other cytokines secreted by these cells, such as TNF-
a, which appears to act synergistically on intestinal
inﬂammation in CD.Supplementary Material
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Supplementary Materials and Methods
Antigen Stimulation of PBMCs
PBMCs were isolated from heparinized peripheral blood
of healthy controls or patients with CD by Ficoll (Sigma-
Aldrich) gradient centrifugation. Cells were cultured in
X-VIVO 15 medium (Bio Whittaker, Lonza, Belgium)
supplemented with 2% inactivated AB human serum
(Sigma-Aldrich) for 7 days. For T-cell proliferation
screening, 1  105 PBMCs were cultured with the microbial
commensal antigens ASCA-Ag, CBir1, FlaX, A4-ﬂa2, and YidX
(Prometheus Laboratories, Inc) at 1 mg/mL for 7 days.
Human r-IL2 (20 IU/mL; eBioscience) was added on day 3
of culture. On day 6, tritiated thymidine (1 mCi/well;
Amersham) was added to the culture in triplicate. The 3H
thymidine incorporation took place during the last 16 hours
of culture. For major histocompatibility complex-II blocking,
anti–HLA-DR, -DP, -DQ (BD Pharmingen) was added at
20 mg/mL to the culture. For CFSE (Cell Trace CFSE cell
proliferation kit; Life Technologies) staining, freshly
isolated PBMCs were incubated with CFSE at 5 mmol/L
according to the supplier’s instructions. Cells then were
plated at 1  106 cells/mL and cultured with TT (Sigma-
Aldrich) and microbial commensal antigens (Prometheus
Laboratories, Inc), all at 2 mg/mL for 7 days.
Enzyme-Linked Immunosorbent Assays
of Serum Antimicrobial Antibodies
Serum antibodies to FlaX, A4-ﬂa2, and YidX were
measured by enzyme-linked immunosorbent assay in 37
samples (18 healthy individuals and 19 CD patients).
Brieﬂy, enzyme-linked immunosorbent assay plates were
coated at 4C overnight with 4 mg/well of FlaX, A4-ﬂa2,
YidX, or with an irrelevant protein for nonspeciﬁc back-
ground subtraction. Plates were blocked with 3% bovine
serum albumin in phosphate-buffered saline for 1.5 hours
at room temperature. After washing, serum was added at
1:100 dilution in 0.1% bovine serum albumin–phosphate-
buffered saline for 2 hours at room temperature. Afterward,
plates were washed and incubated for 1 hour with a
1:50,000 dilution of a horseradish-peroxidase–conjugated
goat anti-human g chain speciﬁc antibody (Jackson Immu-
noResearch Labs, West Grove, PA). After washing, plates
were incubated with tetramethylbenzidine substrate
(eBioscience). Absorbance was read at 620 nm on a
microplate reader (Molecular Devices, Sunnyvale, CA).
Speciﬁc optical density was calculated for each sample and
antigen after subtracting its background optical density.
Seroreactivity to each antigen was determined as an
optical density value greater than the mean optical density
± standard deviation in a group of healthy controls.
Flow Cytometry
For intracellular cytokine staining, cells were restimu-
lated with phorbol myristate acetate and ionomycin in
the presence of brefeldin A (all from Sigma-Aldrich) at
25 ng/mL, 0.5 mg/mL, and 10 mg/mL, respectively, for the
ﬁnal 4 hours of culture. Cells were ﬁxed and permeabilized
with FIX and PERM (Caltag, Life Technologies) according to
the manufacturer’s instructions. Cells were stained with a
LIVE/DEAD ﬁxable violet dead cell stain kit (Life Technol-
ogies), anti-CD4 (RPA-T4; BD Biosciences), anti-IL17 (clone
64DE17; eBioscience), and anti–IFN-g (clone 4S.B3; eBio-
science) conjugated with different ﬂuorochromes.
To assess the expression of integrin b7 on viable CFSE-
CD4þ cells, the antibody anti–integrin b7 (clone FIB504; BD
Biosciences) was used.
Stained cells were acquired in a Fluorescence-Activated
Cell Sorting Canto II (BD Bioscience) and analyzed with BD
Biosciences Fluorescence-Activated Cell Sorting Diva Soft-
ware v6.1.1.
Soluble Cytokine and Chemokine Analysis
For IL17 detection capture and detection, antibodies
were obtained from eBioscience. For IFN-g an enzyme-
linked immunosorbent assay kit (BD OptEIA, Human
IFN-g Enzyme-Linked Immunosorbent Assay Set, BD
Biosciences) was used following the manufacturer’s in-
structions. Simultaneous detection of IL17A, IL17F, IL22,
CCL20, IFN-g, and TNF-a in the supernatants of antigen-
speciﬁc CD4þ T cells was performed using the multiplex
cytokine assay MILLIPLEX Human Th17 magnetic bead
(EMD Millipore Corporation).
For the detection of chemokines in crypt culture super-
natants, enzyme-linked immunosorbent assay kits were used.
For CXCL1 (Human CXCL1/GROa DuoSet Enzyme-Linked
Immunosorbent Assay), CXCL10 (Human CXCL10/IP-10
DuoSet Enzyme-Linked Immunosorbent Assay), and for
CXCL8 (Human CXCL8/IL-8 DuoSet ELISA) enzyme-linked
immunosorbent assay kits were used, all from R&D
Systems. They were used according to the manufacturer’s
instructions.
Cell Sorting of Antigen-Speciﬁc CD4þ T Cells
and RNA Isolation
CFSE-labeled PBMCs were cultured in the presence of
TT, FlaX, A4-ﬂa2, or YidX antigens at 2 mg/mL. Recombinant
IL2 (R&D systems) (20 IU/mL) was added to the culture on
day 7. Cells were harvested at day 14, washed, and stained
using a LIVE/DEAD ﬁxable violet dead cell stain kit (Life
Technologies) and anti-CD4- (RPA-T4; BD Bioscience).
Viable CFSE- CD4þ cells were sorted in a Fluorescence-
Activated Cell Sorting Aria II and cultured with autologous
irradiated PBMCs pulsed with 2 mg/mL of TT, FlaX, A4-ﬂa2,
or YidX. IL2 (10 IU/mL) was added on day 5. After 10–12
days of culture, T cells were harvested, washed in PBS, and
resuspended in TRIzol (Ambion, Foster City, CA). RNA was
isolated using RNeasy kit (Qiagen, Hilden, Germany) ac-
cording to the supplier’s instructions.
Intestinal Crypt Isolation and Culture
Non-IBD intestinal epithelial crypts were isolated from
intestinal tissue as previously described.1 For short-term
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crypt culture, 30 isolated crypts/25 mL Matrigel (BD Bio-
sciences) were plated and cultured in either complete
crypt culture medium: advanced Dulbecco’s modiﬁed Eagle
medium/F12 (Thermo Fisher Scientiﬁc), GlutaMax
(Thermo Fisher Scientiﬁc), 10 mmol/L HEPES (Sigma), N-2
(1) (Thermo Fisher Scientiﬁc), B-27 without retinoic acid
(1) (Thermo Fisher Scientiﬁc), 1 mmol/L N-acetyl-L-
cysteine (Sigma), 500 ng/mL RSPO1 (Sino Biologicals,
Beijing, China), 100 ng/mL human Noggin (Peprotech,
Rocky Hill, NJ), 500 nmol/L LY2157299 (Axon MedChem,
Groningen, The Netherlands), normocin 100 mg/mL and 1
mmol/L valproic acid (Sigma-Aldrich), or in medium con-
taining supernatants from activated sorted antigen-speciﬁc
CD4þ T cells (1:1). Antigen-speciﬁc T-cell supernatants
were obtained from restimulating 1  105 cells with anti-
CD3 (BD Biosciences) and anti-CD28 (BD Biosciences) at 1
mg/mL for 5 days.
Neutralization of IL17 was achieved by preincubation of
T-cell supernatants for 1 hour with monoclonal anti-IL17A
(R&D Systems). After overnight culture at 37C and 5%
CO2, Matrigel embedded crypts were resuspended in 500 mL
TRIzol (Ambion) and total RNA was isolated using the
RNeasy Kit (Qiagen).
Microarray Data Analysis
The derived RNA from sorted antigen-speciﬁc CD4þ T
cells was hybridized to a high-density oligonucleotide
Affymetrix Human Genome U219 Array Plate (Affymetrix
Santa Clara, CA). Raw data were analyzed using Bio-
conductor tools (version 2.132) in R (version 3.1.03) using
the CG (guanine-cytosine) content-adjusted robust multi-
array algorithm to normalize and linear models for micro-
array data for differential expression analysis. Microarray
raw data (.cel ﬁles) and processed data are accessible
through GEO series accession number GSE70469. The
transcriptional signature of Th17 or Th17.1 was obtained
from GSE49703.
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA from sorted CD4þ T cells or stimulated
whole crypts was transcribed to complementary DNA
using reverse transcriptase (High Capacity cDNA RT kit,
Applied Biosystems, Carlsbad, CA). Polymerase chain
reaction was performed in TaqMan Universal Polymerase
Chain Reaction Master Mix and probes (Applied Bio-
systems). Reverse transcription was performed in a
96-well thermocycler (Veriti 96W; Applied Biosystems).
TaqMan real-time polymerase chain reaction was used to
detect transcripts of RORC, IL17A, IL17F, CCL20, CCR6,
PTGER2, TBX21, IFNG, TNFA, CXCL1, CXCL8, and CXCL10.
Fluorescence was detected in an ABI PRISM 7500 Fast
RT- Polymerase Chain Reaction System (Applied Bio-
systems). Primers and probes for each sequence were
obtained as inventoried TaqMan gene-expression assays
(Applied Biosystems). B-actin was used as a reference
gene. Fluorescence was detected using an ABI PRISM
7500 Fast RT-Polymerase Chain Reaction System
(Applied Biosystems).
Multiplex Polymerase Chain Reaction
Ampliﬁcation of b Chain Complementarity
Determining Region 3
Total messenger RNA was extracted with an RNeasy Plus
Mini Kit (Qiagen) and reverse-transcripted using oligo-
deoxythymidine primer. As a control of mRNA integrity, the
glyceraldehyde-3-phosphate dehydrogenase gene was
ampliﬁed from all samples. Multiplex polymerase chain re-
action was adapted from Chitnis and Pahwa.4 Ampliﬁcation
mixtures, including 24 Vb gene families, were performed in
15-mL reactions containing 1.2 mL of the forward Vb primer
MIX and 0.75 mL of the reverse Cb primer at 5 mmol/L, 10
each deoxynucleoside triphosphate (2.5 mmol/L), 10 po-
lymerase chain reaction buffer with 2 mmol/L MgCl2, 40 ng
complementary DNA, and 0.6 U of Taq polymerase (Biotools,
Madrid, Spain). Polymerase chain reaction ampliﬁcation was
3 minutes at 97C, 35 cycles of 95C for 30 seconds, 55C
for 30 seconds, and 72C for 1 minute, and 10 minutes at
72C. Primer mixes were as follows: MIX-A (TCR b-variable
9/30/13), MIX-B (TCR b-variable 20/29/12), MIX-C (TCR b-
variable 28/6-5), MIX-D (TCR b-variable 5/25), MIX-G (TCR
b-variable 3/14), and MIX-H (TCR b-variable 5-6/10), 2.5
mmol/L of each primer; MIX-E (TCR b-variable 7/15), MIX-F
(TCR b-variable 4/11), MIX-I (TCR b-variable 6-2/24), and
MIX-J (TCR b-variable 18/27), for which primers were at 1.7
and 3.3 mmol/L, respectively; and MIX-K (TCR b-variable
23) and MIX-L (TCR b-variable 2) at 2.5 mmol/L. For each
multiplex polymerase chain reaction, a negative control was
run in parallel to exclude possible contaminations.
Complementarity Determining Region 3
Length Analysis by Spectratyping
Run-off extension was performed using multiplex poly-
merase chain reaction products as a template and the
reverse primer Cb 5’ labeled with 6-carboxyﬂuorescein
6-FAM, consisting of 3  2 minute cycles at 95C, 2 mi-
nutes at 55C, and 20 minutes at 72C. Fluorescent poly-
merase chain reaction products were run with a size marker
GS400HD (Applied Biosystems) and were length-separated
by the ABI 3130XL analyzer (Applied Biosystems). Data
were analyzed with the software PeakScanner (Applied
Biosystems). Peak areas were quantiﬁed and normalized
with the size marker to determine the total normalized area
corresponding to each TCR b-variable family. To assess the
presence of monoclonal T-cell expansions, the relative
ﬂuorescence intensity was calculated as follows: relative
ﬂuorescence intensity (%) ¼ (peak area/total Vb area).5,6 A
complementarity determining region 3 peak with a relative
ﬂuorescence intensity greater than 50% was considered a
monoclonal expansion.
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